Niraparib (Zejula) was approved in 2017 in the US and the EU for maintenance treatment of reoccurring ovarian, fallopian, and primary peritoneal carcinomas, regardless of their BRCA1/2m status, in patients that show complete or partial response to chemotherapy (Mirza et al., 2016) (Del Campo et al., 2019) (Scott, 2017). This evidence concerns the gene BRCA1 and peritoneal carcinoma.